MCQOPTIONS
Saved Bookmarks
MCQOPTIONS
This section includes 15 Mcqs, each offering curated multiple-choice questions to sharpen your Protein Engineering knowledge and support exam preparation. Choose a topic below to get started.
| 1. |
Which of the following factor is also known as an anti-hemophilic factor? |
| A. | Factor VII |
| B. | Factor V |
| C. | Factor VI |
| D. | Factor VIII |
| Answer» E. | |
| 2. |
Where in the cell does the cleavage of B domain (of FVIII) occurs by protease furin? |
| A. | Endoplasmic Reticulum |
| B. | Mitochondria |
| C. | cis region of golgi apparatus |
| D. | trans region of golgi apparatus |
| Answer» E. | |
| 3. |
Which of the following is responsible for the activation of factor X (FX) during sustained coagulation?a) Activated Factor V (FVa)b) Activated Factor VIII (FVIIIa)c) Activated Factor XII (FXIIa)d) Activated Factor IX (FIX |
| A. | Activated Factor V (FVa) |
| B. | Activated Factor VIII (FVIIIa) |
| C. | Activated Factor XII (FXIIa) |
| D. | Activated Factor IX (FIXa) |
| Answer» E. | |
| 4. |
The FVIII heavy chain and light chain dissociate after cleavage by the furin. |
| A. | True |
| B. | False |
| Answer» C. | |
| 5. |
Which of the following domain is the cleavage site for furin enzyme? |
| A. | A domain |
| B. | A2 domain |
| C. | C1 domain |
| D. | B domain |
| Answer» E. | |
| 6. |
Which of the following clotting factor is deficient in people suffering from haemophilia B? |
| A. | Factor V |
| B. | Factor VII |
| C. | Factor VIII |
| D. | Factor IX |
| Answer» E. | |
| 7. |
Factor VIII predominantly circulates as a homodimer. |
| A. | True |
| B. | False |
| Answer» C. | |
| 8. |
What is the molecular weight of full length FVIII protein? |
| A. | 170 kDa |
| B. | 210 kDa |
| C. | 310 kDa |
| D. | 280 kDa |
| Answer» E. | |
| 9. |
Which of the following mostly activates FVIII during coagulation? |
| A. | Plasmin |
| B. | Furin |
| C. | Fibrin |
| D. | Thrombin |
| Answer» E. | |
| 10. |
Which of the following is the first non-factor prophylactic bypassing agent that was recently approved for haemophilia A patients with and without inhibitors? |
| A. | Tocilizumab |
| B. | Itolizumab |
| C. | Hemilizumab |
| D. | Emicizumab |
| Answer» E. | |
| 11. |
Most early gene therapy studies were focused on haemophilia B, despite the fact that haemophilia B accounts for only 20 % of all haemophilia cases. |
| A. | False |
| B. | True |
| Answer» C. | |
| 12. |
Which of the following is a bypassing agent, that circumvents the inhibitor to provide hemostasis?a) Recombinant factor X (FX)b) Recombinant factor IX (FIX)c) Recombinant activated factor VIII (FVIIIa)d) Recombinant activated factor VII (FVII |
| A. | Recombinant factor X (FX) |
| B. | Recombinant factor IX (FIX) |
| C. | Recombinant activated factor VIII (FVIIIa) |
| D. | Recombinant activated factor VII (FVIIa) |
| Answer» E. | |
| 13. |
In majority of the cases haemophilia A is inherited as an X-linked recessive trait. |
| A. | False |
| B. | True |
| Answer» C. | |
| 14. |
Which of the following clotting factor is deficient in people suffering from haemophilia A? |
| A. | Factor V |
| B. | Factor VI |
| C. | Factor IX |
| D. | Factor VIII |
| Answer» E. | |
| 15. |
Which of the following is not likely to play a role in clotting of blood? |
| A. | Fibrinogen |
| B. | Platelets |
| C. | Clotting factors |
| D. | Antibodies |
| Answer» E. | |